Anticancer Therapies – Products

This article examines recent advancements in cell therapy research, from promising lab findings poised for clinical translation to enhancements in development, testing, and manufacturing processes.

In this article, Mark Lawler, professor of digital health, answers your questions about these revolutionary techniques and discusses the barriers to their implementation in the clinic. Prof. Lawler has an international reputation in cancer research and a focus on developing a molecular understanding of cancer to improve patient care, including through precision medicine.

One factor that can significantly impact the success of oncology drug development is the preclinical model used. The right model can provide valuable insights into key interactions within the body and help researchers to better understand how tumors respond to treatment.

Chimeric antigen receptor (CAR) therapies involve the use of engineered receptors capable of redirecting immune cells to recognize and destroy cancer cells expressing a specific antigen. Currently, CAR T cells dominate the field of CAR therapy.

InSphero, and ATCC, will work together to introduce new paradigms in the rapidly evolving field of 3D cell-based oncology research.

Encouraging preliminary data from the ongoing DIPG clinical study to be presented at the 2023 Society for Neuro-Oncology Annual Meeting in Vancouver.

Xsphera Biosciences, is pleased to announce the formalization of a Memorandum of Understanding (MOU) with NEX-I, a Seoul-based pioneer in immune-oncology therapeutics.

This literature review explores the latest in 3D immune cell killing assays for cancer immunotherapy research.

Extended long-term collaboration to provide significant additional bioconjugation capacity for commercialization of antibody-drug conjugates (ADCs) for use against hard-to-treat cancers.

Carcinotech and CELLINK plan to revolutionize the drug discovery market by leveraging CELLINK’s bioprinting solutions and Carcinotech’s expertise in producing 3D bioprinted living tumors to provide protocols for users to develop cutting-edge cancer models.